Conclusion
Congruent with expectation, our review demonstrated that compliance to
iron chelators maximises the benefits of the therapy in reducing serum
ferritin, iron overload complications and HRQoL. The serum ferritin
levels appear to be the most
affected outcome by compliance, while
the relationship between ICT
compliance, iron overload complications, and HRQoL was shown but further
investigation is needed. To fully understand the impact of compliance on
the most vulnerable patient groups, more comprehensive research with
larger sample size and comparing the impact of ICT to the outcomes of
interest among different age groups is needed.